Alector(US:ALEC)2025-02-27 03:51Financial Status & Pipeline - Alector had $413.4 million in cash, cash equivalents, and marketable securities as of December 31, 2024, providing a runway through 2026[17, 18] - Alector is targeting 2 INDs (Investigational New Drug) in 2026[9] - Alector's IP portfolio contains 60+ patent families, including 128 issued patents and >500 pending patent applications[16] PGRN Programs & Clinical Trials - Pivotal Phase 3 data for Latozinemab in FTD (frontotemporal dementia) is expected by Q4 2025[9, 49, 68] - Phase 2 enrollment for AL101 in AD (Alzheimer's disease) is expected to be completed by mid-2025[9, 57, 68] - In the INFRONT-2 trial, Latozinemab treatment decreased Glial Fibrillary Acidic Protein (GFAP) levels towards the range seen in asymptomatic carriers of FTD-GRN mutation[35] - Preliminary data from INFRONT-2 suggests Latozinemab may slow disease progression in FTD-GRN participants by approximately 48% compared to matched historical controls, representing a 3.1 point change in CDR® plus NACC FTLD-SB[45] Collaboration with GSK - Alector has a profit-sharing collaboration with GSK for multiple PGRN product candidates[9] - The collaboration includes $700 million upfront payments and $1.5 billion+ in potential milestone payments[68] ABC Technology - Alector Brain Carrier (ABC) technology platform is designed to enhance the delivery of biologics across the blood-brain barrier (BBB)[9, 13] - The ABC technology aims to improve outcomes while reducing costs by enhancing delivery of therapeutics to achieve deeper brain penetration at lower doses[13]